Drug Profile

Research programme: ULK small molecule inhibitors - Erasca

Alternative Names: ERAS-5; ERAS-5 programme - Erasca

Latest Information Update: 09 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator LifeArc
Developer Erasca
Class Antineoplastics; Small molecules
Mechanism of Action Autophagy-related protein-1 homolog inhibitors; Ulk2 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Solid tumours

Most Recent Events

31 Dec 2022 Erasca has patent pending for ULK1 and ULK2 inhibitors, their preparation and method of use
31 Dec 2022 Erasca has worldwide protection for ULK1 and ULK2 inhibitors, their preparation and method of use
02 Sep 2021 Erasca in-licenses inhibitors of ULK1 and ULK2 from LifeArc for the treatment of cancer

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com